comparemela.com

Latest Breaking News On - Autoimmune myasthenia - Page 3 : comparemela.com

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesUnited kingdomSamantha mastersonKelsey kirkJamesf howard jrHoward jf jrSteve millerVan hauwermeirenBeth delgiaccoTim van hauwermeirenDepartment of neurologyZai labDrug administrationExchange commissionMyasthenia gravis foundation of americaEuropean medicines agency

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis | Antibodies

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

United statesJamesf howard jrSamantha mastersonHoward jf jrSteve millerVan hauwermeirenTim van hauwermeirenDepartment of neurologyZai labDrug administrationMyasthenia gravis foundation of americaEuropean medicines agencyCigna corpDevices agencyImmunology innovation programJapan pharmaceuticals

argenx SE: argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

VYVGART is the first-and-only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65)

United statesUnited kingdomMichelle greenblattSamantha mastersonKelsey kirkJamesf howard jrHoward jf jrSteve millerBeth delgiaccoVan hauwermeirenTim van hauwermeirenDepartment of neurologyZai labDrug administrationExchange commissionMyasthenia gravis foundation of america

vimarsana © 2020. All Rights Reserved.